Manufacturing / Biological Products, Except Diagnostic Substances
IOVANCE BIOTHERAPEUTICS, INC.
IOVA
$8.44
+$0.38 (+4.66%)
Price as of Aug 25, 2026 16:08 UTC
3.7 B
Market Cap (Mid Cap)
7%
IV Rank
99.8%
Implied Volatility
Nov 04
Next Earnings
Price & Trend
Daily candles with EMA 20, SMA 50. Drag to zoom.
Options Activity & Greeks
Implied volatility, flow, and dealer positioning from the options market.
Put/Call Ratio
1.04
Balanced
Implied Volatility
99.8%
0% percentile
IV vs Realized
Options cheap
30d HV 140.6%
Options Heat Map
Delta-risk grid for IOVA options across strikes and expirations. Hover any cell for full Greeks.
Loading option chain data...
Insider Trades
3 buys
0 sells
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| Aug 10, 2026 | Kirby Daniel Gordon | Exercise | 10,001 | $0 | |
| Aug 10, 2026 | Kirby Daniel Gordon | Tax_withholding | 2,436 | $15,590 | |
| Aug 10, 2026 | Kirby Daniel Gordon | Exercise | 10,001 | $0 | |
| Aug 06, 2026 | Roche Corleen M. | Exercise | 49,995 | $0 | |
| Aug 06, 2026 | Roche Corleen M. | Tax_withholding | 21,238 | $131,888 | |
| Aug 06, 2026 | Roche Corleen M. | Exercise | 49,995 | $0 | |
| Jun 16, 2026 | WEISER MICHAEL | Grant | 90,316 | $0 | |
| Jun 16, 2026 | Maynard Ryan D | Grant | 90,316 | $0 | |
| Jun 16, 2026 | Puri Raj K. | Grant | 15,000 | $0 | |
| Jun 16, 2026 | Countouriotis Athena | Grant | 90,316 | $0 |
Earnings History
| Date | Quarter | EPS Est. | EPS Actual | Surprise | Result |
|---|---|---|---|---|---|
| Aug 06, 2026 | Q2 2026 | -$0.13 | |||
| Aug 05, 2026 | Q2 2026 | -$0.13 | |||
| Jun 30, 2026 | Q2 2026 | -$0.13 | -$0.11 | +14.3% | Beat |
| Mar 31, 2026 | Q1 2026 | -$0.15 | -$0.19 | -24.3% | Miss |
| Dec 31, 2025 | Q4 2025 | -$0.18 | -$0.18 | -2.8% | Miss |
| Sep 30, 2025 | Q3 2025 | -$0.26 | -$0.25 | +5.0% | Beat |
| Jun 30, 2025 | Q2 2025 | -$0.29 | -$0.33 | -13.7% | Miss |
| Mar 31, 2025 | Q1 2025 | -$0.24 | -$0.36 | -47.5% | Miss |
Track IOVA with ThetaPal
Get insider trade alerts, AI portfolio analysis, and options roll recommendations for IOVA and your entire portfolio.